Biogen is continuing to actively recruit Alzheimer’s patients for its Phase 4 ICARE AD-US trial, which is evaluating the long-term safety and effectiveness of Aduhelm (aducanumab) in the real-world U.S. clinical setting. Participants — including a targeted enrollment of 16% Latino and African American patients — are currently being enrolled at more than 10 sites in the U.S., with up to 200 sites expected to open. Further information on contacts and locations can be found here.…
April 29, 2022April 29, 2022